Rendering

Component: (Network and Table)
Network
2418408 - Disclosure - Segments of Business and Geographic Areas (Details 6)
(http://www.jnj.com/role/SegmentsOfBusinessAndGeographicAreasDetails6)
TableSchedule of Revenues from External Customers and Long-Lived Assets [Table]
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000200406 (http://www.sec.gov/CIK)
Revenues from External Customers and Long-Lived Assets [Line Items]Period [Axis]
2013-09-30 - 2013-12-29
2013-07-01 - 2013-09-29
2013-04-01 - 2013-06-30
2012-12-31 - 2013-12-29
2012-12-31 - 2013-03-31
2012-10-01 - 2012-12-30
2012-07-02 - 2012-09-30
2012-04-02 - 2012-07-01
2012-01-02 - 2012-12-30
2012-01-02 - 2012-04-01
2011-01-03 - 2012-01-01
Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]Geographical [Axis]
UNITED STATESEurope [Member]Western Hemisphere, excluding U.S. [Member]Asia-Pacific, Africa [Member]General Corporate [Member]Geographical [Domain]Geographical [Domain]Geographical [Domain]UNITED STATESEurope [Member]Western Hemisphere, excluding U.S. [Member]Asia-Pacific, Africa [Member]Operating Segments [Member]General Corporate [Member]Geographical [Domain]Geographical [Domain]UNITED STATESEurope [Member]Western Hemisphere, excluding U.S. [Member]Asia-Pacific, Africa [Member]General Corporate [Member]Geographical [Domain]Geographical [Domain]Geographical [Domain]UNITED STATESEurope [Member]Western Hemisphere, excluding U.S. [Member]Asia-Pacific, Africa [Member]Operating Segments [Member]General Corporate [Member]Geographical [Domain]Geographical [Domain]UNITED STATESEurope [Member]Western Hemisphere, excluding U.S. [Member]Asia-Pacific, Africa [Member]Operating Segments [Member]General Corporate [Member]Geographical [Domain]
Long-Lived Assets
35,880,000,000 1
24,868,000,000 1
3,281,000,000 1
2,434,000,000 1
992,000,000 1
66,463,000,000 1
 
 
35,880,000,000 1
24,868,000,000 1
3,281,000,000 1
2,434,000,000 1
 
992,000,000 1
66,463,000,000 1
 
35,115,000,000 1
25,261,000,000 1
3,636,000,000 1
2,362,000,000 1
899,000,000 1
66,374,000,000 1
 
 
35,115,000,000 1
25,261,000,000 1
3,636,000,000 1
2,362,000,000 1
 
899,000,000 1
66,374,000,000 1
 
23,529,000,000 1
19,056,000,000 1
3,517,000,000 1
2,163,000,000 1
 
750,000,000 1
48,265,000,000 1
Other non long-lived assets
 
 
 
 
 
65,228,000,000 1
 
 
 
 
 
 
 
 
65,228,000,000 1
 
 
 
 
 
 
54,074,000,000 1
 
 
 
 
 
 
 
 
54,074,000,000 1
 
 
 
 
 
 
 
64,629,000,000 1
Worldwide total
 
 
 
 
 
132,683,000,000 1
 
 
 
 
 
 
 
 
132,683,000,000 1
 
 
 
 
 
 
121,347,000,000 1
 
 
 
 
 
 
 
 
121,347,000,000 1
 
 
 
 
 
 
 
113,644,000,000 1
Sales Revenue, Goods, Net
 
 
 
 
 
18,355,000,000 2
17,575,000,000 3
17,877,000,000 4
31,910,000,000  
18,599,000,000  
7,421,000,000  
13,382,000,000  
71,312,000,000  
 
71,312,000,000  
17,505,000,000 9
 
 
 
 
 
17,558,000,000 7
17,052,000,000 5
16,475,000,000 8
29,830,000,000  
16,945,000,000  
7,207,000,000  
13,242,000,000  
67,224,000,000  
 
67,224,000,000  
16,139,000,000 6
28,908,000,000  
17,129,000,000  
6,418,000,000  
12,575,000,000  
65,030,000,000  
 
65,030,000,000  
1: Long-lived assets include property, plant and equipment, net for 2013, 2012 and 2011 of $16,710, $16,097 and $14,739, respectively, and intangible assets and goodwill, net for 2013, 2012 and 2011 of $50,745, $51,176 and $34,276, respectively.
2: The fourth quarter of 2013 includes after-tax charges of $227 million from net litigation expense, $110 million from Synthes integration/transaction costs, $294 million from impairment of in-process research and development, $118 million associated with the DePuy ASR™ Hip program and a $707 million tax benefit associated with Scios Inc.
3: The third quarter of 2013 includes after-tax charges of $720 million from net litigation expense, $103 million from Synthes integration/transaction costs, $126 million from impairment of in-process research and development and $31 million associated with the DePuy ASR™ Hip program.
4: The second quarter of 2013 includes after-tax charges of $308 million from net litigation expense, $87 million from Synthes integration/transaction costs and $61 million associated with the DePuy ASR™ Hip program
5: The third quarter of 2012 includes after-tax charges of $135 million associated with the acquisition of Synthes, Inc., $340 million from impairment of in-process research and development, $70 million associated with net litigation expense, and $24 million associated with the DePuy ASR™ Hip program.
6: The first quarter of 2012 includes an after-tax gain of $106 million from currency and costs associated with the acquisition of Synthes, Inc.
7: The fourth quarter of 2012 includes after-tax charges of $371 million from net litigation expense, $306 million associated with the acquisition of Synthes, Inc., $73 million associated with the DePuy ASR™ Hip program and $59 million from impairment of in-process research and development.
8: The second quarter of 2012 includes after-tax charges of $717 million for asset write-downs, $611 million from net litigation expense, $564 million associated with the acquisition of Synthes, Inc. and $344 million from impairment of in-process research and development.
9: The first quarter of 2013 includes after-tax charges of $183 million from Synthes integration/transaction costs, $391 million from net litigation expense and $42 million from impairment of in-process research and development, and $30 million associated with the DePuy ASR™ Hip program.